Blog Vox: Lipid nanoparticles are essential to Covid vaccines March 3, 2021 Andrey Zarur, CEO of GreenLight Biosciences, speaks to Vox about the short supply of lipid nanoparticles for Covid-19 vaccines. Andrey Zarur, CEO of GreenLight Biosciences, speaks to Vox about the short supply of lipid nanoparticles for Covid-19 vaccines. These are a key ingredient that could hold back vaccine manufacturing. Extracts from the article are below: “You basically are squeezing them through tiny little orifices to form these nanodroplets,” explained Andrey Zarur, the co-founder of Greenlight Biosciences, a company working on RNA-based vaccines. At the same time, the facility where this happens also has to be pristine. “[There are] people walking around in bunny suits having gone through a sterile door, and suiting up in that sterile door, having covered everything [and] breathing through respirators,” he explains.“I don’t want to give you the impression that once we solve the lipid nanoparticle issue, then the 16 billion doses for humanity are solved,” said Zarur, of Greenlight Biosciences. “Because the reality is, we solve that bottleneck, and then we’ll find another bottleneck.” Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: Bloomberg: GreenLight Is Mass-Producing RNA to Fight Crop Pests News10NBC: GreenLight Biosciences opens new RNA facility in Rochester The New York Times: Vaccines for Africa GreenLight Biosciences opens RNA production facility for the next generation of agricultural products Jennifer Raymond welcomed as SVP, CMC and Manufacturing STAT: RNA firm GreenLight Biosciences to go public in $1.2 billion deal